Evaluation of maternal plasma platelet activating factor acetylhydrolase activity and mRNA expression in pre-eclampsia: a case control study

References

• ACOG. 2019. Practice Bulletin No. 202: gestational hypertension and preeclampsia. Obstetrics and Gynecology 1:e1–e25.
   Google Scholar
• American College of Obstetricians and Gynecologists (ACOG); Task Force on Hypertension in Pregnancy. 2013. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122:1122–1131.
   PubMed Web of Science ®Google Scholar
• Aggarwal PK, Chandel N, Jain V, Jha V. 2012. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. Journal of Human Hypertension 26:236–241.
   PubMed Web of Science ®Google Scholar
• Barden A, Ritchie J, Walters B, Michael C, Rivera J, Mori T, et al. 2001. Study of plasma factors associated with neutrophil activation and lipid peroxidation in preeclampsia. Hypertension 38:803–808.
   PubMed Web of Science ®Google Scholar
• Benedetto C, Massobrio M, Bertini E, Abbondanza M, Enrieu N, Tetta C. 1989. Reduced serum inhibition of platelet-activating factor activity in preeclampsia. American Journal of Obstetrics and Gynecology 160:100–104.
   PubMed Web of Science ®Google Scholar
• Huppertz B. 2008. Placental Origins of preeclampsia: challenging the current hypothesis. Hypertension 51:970–997.
   PubMed Web of Science ®Google Scholar
• Fan P, Liu XH, He GL, Zhang S, Zhang JX, Bai H. 2012. Maternal and fetal plasma platelet-activating factor acetylhydrolase activity and distribution in pre-eclampsia. Pediatric Research 72:426–431.
   PubMed Web of Science ®Google Scholar
• Gardiner C, Vatish M. 2017. Impact of haemostatic mechanisms on pathophysiology of preeclampsia. Thrombosis Research 151:S48–S52.
   PubMed Web of Science ®Google Scholar
• Gu Y, Burlison SA, Wang Y. 2006. PAF levels and PAF-AH activities in placentas from normal and preeclamptic pregnancies. Placenta 27:744–749.
   PubMed Web of Science ®Google Scholar
• Karasawa K. 2006. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochimica et Biophysica Acta 1761:1359–1372.
   PubMed Web of Science ®Google Scholar
• Kobayashi F, Sagawa N, Ihara Y, Kitagawa K, Yano J, Mori T. 1994. Platelet-activating factor-acetyl hydrolase activity in maternal and umbilical venous plasma obtained from normotensive and hypertensive pregnancies. Obstet Gynecol 84:360–364.
   PubMed Web of Science ®Google Scholar
• Maki N, Magness RR, Miyaura S, Gant NF, Johnston JM. 1993. Platelet-activating factor-acetylhydrolase activity in normotensive and hypertensive pregnancies. American Journal of Obstetrics and Gynecology 168:50–54.
   PubMed Web of Science ®Google Scholar
• Matsubara K, Yano J, Kitagawa H, Ochi H, Suginami H, Sagawa N, et al. 1996. Serum platelet-activating factor acetylhydrolase activity in normal pregnancy and preeclampsia. Hypertension in Pregnancy 15:51–59.
   Web of Science ®Google Scholar
• Myatt L. 2002. Role of placenta in preeclampsia. Endocrine 19:103–111.
   PubMed Web of Science ®Google Scholar
• Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY. 2005. Plasma markers of angiogenesis in pregnancy induced hypertension. Thrombosis and Haemostasis 94:1071–1076.
   PubMed Web of Science ®Google Scholar
• Ohshige A, Yoshimura T, Maeda T, Ito M, Okamura H. 1999. Increased platelet-activating factor-acetylhydrolase activity in the umbilical venous plasma of growth-restricted fetuses. Obstet Gynecol 93:180–183.
   PubMed Web of Science ®Google Scholar
• Olusanya BO, Solanke OA. 2012. Perinatal outcomes associated with maternal hypertensive disorders of pregnancy in a developing country. Hypertension in Pregnancy 31:120–113.
   PubMed Web of Science ®Google Scholar
• Payne BA, Hanson C, Sharma S, Magee LA v, Dadelszen P. 2016. Epidemiology of the hypertensive disorders of pregnancy. In: Magee LA, von Dadelszen P, Stones W, Mathai M, editors. The FIGO textbook of pregnancy hypertension. London: Global Library of Women’s Medicine.
   Google Scholar
• Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. 2000. Platelet-activating factor and related lipid mediators. Annual Review of Biochemistry 69:419–445.
   PubMed Web of Science ®Google Scholar
• Ren Y, Wang H, Qin H, Yang J, Wang Y, Jiang S, et al. 1969. Vascular endothelial growth factor expression in peripheral blood of patients with pregnancy induced hypertension syndrome and its clinical significance. Pakistan Journal of Medical Sciences 30:634–637.
   Google Scholar
• Roberts JM. 1998. Endothelial dysfunction in preeclampsia. Seminars in Reproductive Endocrinology 16:5–15.
   PubMedGoogle Scholar
• Rodie VA, Caslake MJ, Stewart F, Sattar N, Ramsay JE, Greer IA, et al. 2004. Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Atherosclerosis 176:181–187.
   PubMed Web of Science ®Google Scholar
• Sebastian T, Yadav B, Jeyaseelan L, Vijayaselvi R, Jose R. 2015. Small for gestational age births among South Indian women: temporal trend and risk factors from 1996 to 2010. BMC Pregnancy and Childbirth 15:7.
   PubMed Web of Science ®Google Scholar
• Su LH, Liu XH, He GL, Gao Q, Bai H, Fan P. 2015. The Ala379Val polymorphism of platelet-activating factor acetylhydrolase gene in Chinese patients with pre-eclampsia. Sichuan Da Xue Xue Bao Yi Xue Ban 46:108–112.
   PubMedGoogle Scholar
• Tomimatsu T, Mimura K, Matsuzaki S, Endo M, Kumasawa K, Kimura T. 2019. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors. International Journal of Molecular Sciences 20:4246.
   Web of Science ®Google Scholar